A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease: brnw.ch/21wM3U7 Vijaya R Bhatt, MBBS, MS

Omission of #Radiotherapy in Primary Mediastinal B-Cell #Lymphoma: IELSG37 Trial Results: brnw.ch/21wM5ge @Mjerkeman #lymsm

Oral Cannabis Extract for Secondary Prevention of #Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial brnw.ch/21wM5xf @COLBH #PallOnc

📢Calling all oncology researchers! We’re accepting submissions for JCO Oncology Advances. Share impactful cancer research with a global community and contribute to advancing clinical oncology. Submit your work ➡️ brnw.ch/21wM6Ts #JCO #OncologyResearch #OpenAccess

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six #ClinicalTrials. UMC Utrecht Anne May brnw.ch/21wM7aB

🎙️ Listen to JCO’s essay, “It Mattered Later: A Patient Turned Doctor's Perspective on Fertility Loss” by Margaret Cupit-Link. She shares her experience with #childhoodcancer & the importance of educating patients on #fertility preservation options. brnw.ch/21wM7KP #ayacsm

Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With #BreastCancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study brnw.ch/21wM9ue #bcsm

Bevacizumab Erlotinib Switch Maintenance in #Chemo-Responsive Advanced Gallbladder and Cholangiocarcinomas (BEER BTC): A Multicentre, Open-Label, Randomized, Phase II Trial brnw.ch/21wMaUw

JCO Oncology Advances is open for submissions! Rapid publication, broad reach ✔️ Fully open-access & interdisciplinary ✔️ Unique content ✔️ Therapeutic & supportive care articles Submit your research: brnw.ch/21wMbkO #JCO #OncologyResearch #ClinicalOncology

Listen to the latest #JCO Cancer Stories: The Art of Oncology episode "Scotch and Pizza” by Dr. Paul Jansson, who shares his perspective as a critical care physician and discusses how one question can make all the difference. brnw.ch/21wMbAp #OncTwitter

#BreastCancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival brnw.ch/21wMcTr Rita #bcsm

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial: brnw.ch/21wMdrP #pancsm

Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell #AcuteLymphoblasticLeukemia: brnw.ch/21wMem7 #leusm

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected #Melanoma in CheckMate 238: brnw.ch/21wMexu #melsm

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies: brnw.ch/21wMfsU Institute for Experimental Cell Therapy, UK-Essen #hemonc

The HER2 Pan Tumor Indication for Trastuzumab Deruxtecan: brnw.ch/21wMgWx @rigshospitalet

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant Metastatic Nonsquamous Non-Small Cell #LungCancer: brnw.ch/21wMj2H #lcsm #NSCLC

Extent of Lymphadenectomy for Surgical Management of Right-Sided #ColonCancer: The Randomized Phase III RELARC Trial brnw.ch/21wMju7 #crcsm

Menopausal Hormone Therapy and #Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women’s Health Initiative Randomized Trials brnw.ch/21wMln0 #gynonc

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights brnw.ch/21wMlV8